Surbhi Sidana, MD

Articles by Surbhi Sidana, MD

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Surbhi Sidana, MD

Articles by Surbhi Sidana, MD

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

Trending on CancerNetwork

FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

NALIRIFOX Shows Survival Benefit Vs Gemcitabine/Nab-Paclitaxel in Metastatic PDAC

Opportunities for Guiding Neoadjuvant Treatment Decisions with ctDNA in MIBC